BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical & Diagnostic

FDA grants ODD for new NK treatment

The US FDA has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye diseas...

December 08, 2022 | News

EMA Validates Application for Arpraziquantel to Treat Schistosomiasis in Preschool-Aged Children

Arpraziquantel is a potential new treatment option for the estimated 50 million preschool-aged children with schistosomiasis, one of the most devast...

December 06, 2022 | News

JelloX Biotech Leads Research in 3D Cancer Pathology as NCI Explores Potential

Presently, most cancer diagnosis is done through thinly sliced physical biopsies. Though widespread, the amount of information this method collects remains...

December 06, 2022 | News

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer tre...

December 02, 2022 | News

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

The complete manufacturing of BVX-0918 from a cancer patient's ovarian tumor now validates the production protocols that had been in development over the p...

December 02, 2022 | News

Telehealth Usage in Asia Pacific for People Living With Hiv Increasing, but Data Privacy and Lack of Personal Contact Still Seen as a Barrier to Wider Use

Half of the people living with HIV (PLHIV) and individuals at-risk (IARs) surveyed in the region increased their usage of telehealth services over the pa...

November 28, 2022 | News

GE Healthcare Highlights Transformative Precision Innovations and Collaborations that Help Drive the Future of Health

Drawing on more than 100 years of history as a trusted medical technology innovator1, GE Healthcare is closely connected with healthcare systems globally. ...

November 28, 2022 | News

First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of Telix's lead therapeutic clinical programs and has been granted orphan drug designation ...

November 22, 2022 | News

United Imaging Drives Forward Several Major Innovations in Multiple Imaging Modalities

United Imaging, a global leader in producing advanced medical imaging and radiotherapy equipment, announced a series of commercially available and 510...

November 22, 2022 | News

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Summary of Study Outcomes ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met ...

November 07, 2022 | News

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidne...

November 04, 2022 | News

Australia First in-human use of OncoRes Medical's cancer imaging system successful

OncoRes Medical today announces positive data from the first in-cavity use of its Quantitative Micro-Elastography (QME) Imaging System. The study, titled&n...

November 03, 2022 | News

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Selinexor was granted orphan drug designation in MF by the U. S. Food and Drug Administration (FDA) in May 2022. Karyopharm is currently evaluating se...

November 02, 2022 | News

Thermo Fisher Scientific to Acquire The Binding Site Group

Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing...

November 01, 2022 | News

Stay Connected